Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$91.90

2.11 (2.35%)

09:52
12/07/17
12/07
09:52
12/07/17
09:52

Sage Therapeutics price target raised to $191 from $140 at Canaccord

  • 07

    Dec

SAGE Sage Therapeutics
$91.90

2.11 (2.35%)

11/17/17
BMOC
11/17/17
NO CHANGE
Target $112
BMOC
Outperform
Sage Therapeutics price target raised to $112 from $80 at BMO Capital
BMO Capital analyst Gary Nachman raised his price target for Sage Therapeutics to $112 saying he received "very positive" feedback from two leading psychiatrists on the brexanolone Phase 3 data in both severe and moderate postpartum depression. The shares closed yesterday up 20c to $85.67. The physicians are "very impressed" by the rapid onset and good safety profile for brexanolone and expect to use the drug a lot, Nachman tells investors in a research note. The psychiatrists also expressed their belief in a high probability of success for the upcoming SAGE-217 data in postpartum depression and major depressive disorder, the analyst adds. He sees a good risk/reward into those catalysts at current share levels. Nachman reiterates an Outperform rating on Sage.
11/27/17
RBCM
11/27/17
NO CHANGE
Target $137
RBCM
Outperform
Sage Therapeutics price target lowered to $137 from $145 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Sage Therapeutics to $137 from $145, modelling a 40% probability of success and the possibility of more non-responders in the Phase 2B SAGE-217 for major depressive disorder - MDD - treatment. Abrahams keeps Outperform rating, saying the risk-reward profile is still attractive given the likelihood of "many additional shots on goal even if MDD fails", as negative outcome would not necessarily impact the overall prospects of the oral program in post-partum depression.
12/07/17
LEER
12/07/17
NO CHANGE
LEER
Outperform
Sage Therapeutics '217 MDD data looks like best case scenario, says Leerink
Leerink analyst Paul Matteis notes that Sage Therapeutics announced positive data for SAGE-217 in its phase 2 randomized, placebo-controlled study in major depressive disorder, or MDD. The analyst believes the data looks like best case scenario and expects the stock to trade up significantly today. He reiterates an Outperform rating on the shares.
12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Sage Therapeutics data 'best-case scenario,' says JPMorgan
JPMorgan analyst Cory Kasimov views this morning's Phase 2 trial data of SAGE-217 in major depressive disorder as a "best-case scenario." The analyst expects the stock to be up "sharply" today given the strength of the data. He has an Overweight rating on Sage shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.